^
Association details:
| Biomarker: | ERCC2 E606Q |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | gemcitabine (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder Cancer
Published date:
08/26/2020
Excerpt:
The patient (Case #14) was diagnosed with MIBC and had bilateral pelvic lymph node metastases. In this tumor, ERCC2 p.E606Q was identified...this patient was treated with neoadjuvant therapy with carboplatin and gemcitabine...After neoadjuvant therapy, the primary tumor in the bladder and pelvic lymph node metastases had remarkably shrunk...viable tumor cells were not observed in specimens from lymph node dissection....
DOI:
https://doi.org/10.3389/fonc.2020.01643
